Skip to main content
OpenTrials
Completed

NCT Number: NCT05249387

Characterization of Bovine Adrenal Medulla as a New Surrogate Model of Non-histaminergic Itch

With this experiment, the experimenter wish evaluate the role of TRPA1 on non-histaminergic itch induced by BAM8-22

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Itch Pathological Conditions, Signs and Symptoms Pruritus Signs and Symptoms Skin Diseases Skin Manifestations Skin and Connective Tissue Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Giulia Erica Aliotta

Aalborg, 9000, Denmark

About this study

With this experiment, the experimenter wish evaluate the role of TRPA1 on non-histaminergic itch induced by BAM8-22 2 (Bovine Adrenal Medulla), which is found naturally in the human body and which has proved to evoke itch. To evaluate the role of TRPA1 it will be used a TRPA1 antagonist (A-967079)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy men and women
  • 18-60 years
  • Speak and understand English

Exclusion criteria

  • Pregnancy or lactation
  • Drug addiction defined as any use of cannabis, opioids or other drugs
  • Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.)
  • Moles, wounds, scars or tattoos in the area to be treated or tested
  • Lack of ability to cooperate •
  • Current use of medications that may affect the trial such as antihistamines and pain killers.
  • Skin diseases
  • Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain •
  • Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Treatment and study plan

A-967079 and BAM8-22 application

Drug

A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

A-967079 and BAM8-22 application after 5 minutes.

Drug

A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules

A-967079 application.

Drug

A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm

Vehicle and BAM8-22 application.

Drug

Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Primary outcomes

  1. superficial blood perfusion

    Time frame: change from baseline, up to 10 minutes after the application

    is measured by a speckle contrast imager (FLPI, Moor Instruments, England)

  2. Warm Detection Threshold, and Heat Pain threshold

    Time frame: change from baseline, up to 10 minutes after the application

    he tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

  3. Cold Detection Threshold and Cold Pain threshold

    Time frame: change from baseline, up to 10 minutes after the application

    the tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

  4. Pain supra-threshold heat Stimuli

    Time frame: change from baseline, up to 10 minutes after the application

    the tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

  5. Alloknesis

    Time frame: change from baseline, up to 10 minutes after the application

    s measured by using a mildy pruritic, non-painful von Frey filaments of a predetermined intensity (generally 5-30 milliNewton of force)

  6. mechanical pain threshold and sensitivity

    Time frame: change from baseline, up to 10 minutes after the application

    is performed using a pin-prick set (Aalborg University). The set consists of 8 needles each having a diameter of 0,6 mm and different force applications

  7. itch rating

    Time frame: change from baseline, up to 10 minutes after the application

    the subject will rate the itch for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates "no itch" and 100 indicates "worst imaginable itch"

Secondary outcomes

  1. pain rating

    Time frame: change from baseline, up to 10 minutes after the application

    the subject will rate the pain for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates "no pain" and 100 indicates "worst imaginable pain"

Sponsors and collaborators

Lead sponsor

Aalborg University

Other

Registry information

Official study title

Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 21, 2022
Registry last updated
Sep 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.